SAMIL PHARMACEUTICAL (000520) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SAMIL PHARMACEUTICAL (000520) reported revenue of 210.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025210.3 billion KRW-22.2 billion KRW-34.7 billion KRW[source]
2024219.7 billion KRW113 million KRW-5.6 billion KRW[source]
2023196.3 billion KRW6.5 billion KRW1.7 billion KRW[source]
2022179.7 billion KRW4.0 billion KRW-28 million KRW[source]
2021134.2 billion KRW400 million KRW-5.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025363.0 billion KRW207.6 billion KRW155.5 billion KRW[source]
2024360.7 billion KRW192.5 billion KRW168.2 billion KRW[source]
2023344.9 billion KRW223.3 billion KRW121.6 billion KRW[source]
2022314.8 billion KRW194.5 billion KRW120.3 billion KRW[source]
2021223.6 billion KRW158.5 billion KRW65.1 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025568 million KRW-8.0 billion KRW8.7 billion KRW[source]
20242.6 billion KRW-6.4 billion KRW8.0 billion KRW[source]
202311.7 billion KRW-19.8 billion KRW8.5 billion KRW[source]
20224.2 billion KRW-35.9 billion KRW29.7 billion KRW[source]
20211.4 billion KRW-45.3 billion KRW31.9 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice